Hemogenyx Pharmaceuticals Balance Sheet

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	1.59	0.16	1.25	2.53	6.84
Cash & Short-Term Investments	1.59	0.16	1.25	2.53	6.84
Cash Growth	896.10%	-87.23%	-50.74%	-62.98%	277.48%
Accounts Receivable	0.45	0.68	0.92	0.06	0.3
Total Current Assets	2.03	0.84	2.17	2.59	7.14
Net Property, Plant & Equipment	1.8	2.73	3.31	3.92	0.8
Other Intangible Assets	0.18	0.48	0.47	0.44	0.44
Other Long-Term Assets	0.16	0.17	0.15	0.14	0.14
Total Assets	4.18	4.21	6.11	7.09	8.52
Accounts Payable	1.03	0.73	0.38	0.43	0.34
Current Portion of Leases	0.44	0.42	0.36	0.32	0.01
Total Current Liabilities	1.47	1.16	0.74	0.75	0.35
Long-Term Leases	1.56	2.2	2.58	3.1	-
Total Long-Term Liabilities	1.56	2.2	2.58	3.1	-
Total Liabilities	3.03	3.36	3.32	3.85	0.35
Common Stock	14.04	14.02	11.76	9.8	9.8
Additional Paid-in Capital	29.24	21.39	19.94	16.81	16.81
Accumulated Other Comprehensive Income	-3.34	-5.09	-5.07	-6.22	-5.28
Retained Earnings	-38.75	-29.42	-23.8	-17.11	-13.13
Total Common Shareholders' Equity	1.2	0.9	2.82	3.28	8.19
Minority Interest	-0.05	-0.04	-0.04	-0.03	-0.02
Shareholders' Equity	1.14	0.85	2.78	3.24	8.17
Total Liabilities & Equity	4.18	4.21	6.11	7.09	8.52
Total Debt	2	2.62	2.95	3.42	0.01
Net Cash (Debt)	-0.42	-2.46	-1.7	-0.89	6.83
Net Cash Growth	-	-	-	-	3609.03%
Net Cash Per Share	-0.09	-0.75	-0.60	-0.36	3.53
Book Value	1.2	0.9	2.82	3.28	8.19
Book Value Per Share	0.27	0.27	1.00	1.34	4.23
Tangible Book Value	1.01	0.42	2.35	2.83	7.75
Tangible Book Value Per Share	0.23	0.13	0.83	1.16	4.01